This study is in progress, not accepting new patients
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles 5368361, California 5332921 and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Nicholas P. McAndrew, MD, MSCE

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Nicholas P. McAndrew, MD, MSCE
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 19 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- Links
- Breast Cancer Study Locator details (for US) Sign up for this study
- ID
- NCT06112379
- Phase
- Phase 3 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- About 1902 people participating
- Last Updated